Author

A. Soragni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 3 Assay:organoid / primary culture· 3 Approach:deep learning· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

A. Davarifar· 3 shared H. T. L. Nguyen· 3 shared N. Tavanaie· 3 shared A. Al Shihabi· 2 shared F. Hornicek· 2 shared J. Yanagawa· 2 shared N. Bernthal· 2 shared N. Federman· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Davarifar

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The landscape of drug sensitivity and resistance in sarcoma

A. Al Shihabi, P. J. Tebon, H. T. L. Nguyen, J. Chantharasamee, S. Sartini, A. Davarifar, A. Y. Jensen, M. Diaz-Infante, H. Cox, A. Enrique-Gonzalez, S. Swearingen, N. Tavanaie, S. Dry, A. Singh, B. Chmielowski, , A. Soragni

This study uses patient-derived tumor organoids to identify drug sensitivity and resistance patterns in sarcoma, finding actionable treatment regimens for 59% of tested specimens.

bioRxiv · May 25, 2023Cancer Biology

Drug screening at single-organoid resolution via bioprinting and interferometry

P. J. Tebon, B. Wang, A. L. Markowitz, A. Davarifar, P. Krawczuk, G. Murray, H. T. L. Nguyen, N. Tavanaie, T. L. Nguyen, P. C. Boutros, M. A. Teitell, A. Soragni

The paper develops a method to screen drugs at single-organoid resolution using bioprinting and interferometry to identify treatment responses in tumor organoids.

bioRxiv · Oct 3, 2021Bioengineering

Personalized chordoma organoids for drug discovery studies

A. Al Shihabi, A. Davarifar, H. T. L. Nguyen, N. Tavanaie, S. D. Nelson, J. Yanagawa, N. Federman, N. Bernthal, F. Hornicek, A. Soragni

This study establishes patient-derived chordoma organoids to identify effective targeted therapies, finding PI3K/mTOR, EGFR, and JAK2/STAT3 inhibitors as promising candidates.

bioRxiv · May 27, 2021Cancer Biology

A simple high-throughput approach identifies actionable drug responses in patient-derived tumor organoids

N. Phan, J. J. Hong, B. Tofig, M. Mapua, D. Elashoff, N. A. Moatamed, J. Huang, S. Memarzadeh, R. Damoiseaux, A. Soragni

This paper introduces a high-throughput method for drug screening using tumor organoids and identifies effective drugs for ovarian cancer within a week of surgery.

bioRxiv · Aug 13, 2018Cancer Biology